Focus: Cancer Center Featured Story 2

• share
• favorite_border

Study in Nature Nanotechnology describes new method to transform immune cells, while inside the body, into leukemia-fighting powerhouses

• share
• favorite_border

The third annual “Splash Away Cancer!” fundraising event takes place May 20, 2017. All proceeds support patient care and cancer research programs at The University of New Mexico Comprehensive Cancer Center.

• share
• favorite_border

Nonprofit cancer immunotherapy research organization hires pharmaceutical executive to lead its clinical trials program

• share
• favorite_border

New UC Project Finds Roadmap to Improve Patient Safety in Radiation Exposure

• share
• favorite_border

An international team of collaborators retroactively examined the associations between survival among patients diagnosed with invasive epithelial ovarian cancer and those patients’ history of hypertension, heart disease, diabetes, and medications taken for those conditions. They found that while hypertension was linked to better outcomes, diabetes was associated with decreased survival.

• share
• favorite_border

University of Colorado Cancer Center Study uncovers discrepant decision-making for use of 21-gene assay in women with cancer: • Testing occurs in high-risk population, despite current evidence • Non-concordance with NCCN Guidelines® recommendations • Racial and socio-economic disparities found in testing use

• share
• favorite_border

• share
• favorite_border

An international effort to analyze the entire database of Ebola virus genomes from the 2013-2016 West African epidemic reveals insights into factors that sped or slowed the rampage and calls for using real-time sequencing and data-sharing to contain future viral disease outbreaks.

• share
• favorite_border

Scientists at The Wistar Institute have unveiled part of the protein complex that protects telomeres—the ends of our chromosomes.

• share
• favorite_border

Celebrating all types of libraries during National Library Week (April 9 - 16), Rutgers Cancer Institute of New Jersey is recognizing its own patient resources at its specialized library.

• share
• favorite_border

A biochemical analysis study has discovered a new role for the DNA2 enzyme. The research, which was completed in the lab of Patrick Sung, professor of molecular biophysics and biochemistry at the Yale School of Medicine, looked at the way in which DNA2 repairs breaks in DNA that lead to the abnormalities that cause cancer.

• share
• favorite_border

The Lobos vs. Cancer Gala event, which celebrates its tenth year on Saturday, May 20, raises money for cancer research and treatment at UNM Cancer Center.

• share
• favorite_border

After 4-week trial of added rice bran, navy bean powder or neither, both the rice bran and navy bean groups showed increased dietary fiber, iron, zinc, thiamin, niacin, vitamin B6, folate, and alpha-tocopherol. The rice bran group also showed increased microbiome richness and diversity. When researchers treated colorectal cancer cells with stool extracts from these groups, they saw reduced cell growth from the groups that had increased rice bran and navy bean consumption.

• share
• favorite_border

Dr. Kristin Anderson from Fred Hutch will describe preclinical research on T-cell therapy showing how engineered T cells are able to kill both human and mouse ovarian cancer cells in the lab and significantly extend survival in a mouse model.

• share
• favorite_border

Oncora Medical, a precision radiation oncology software company, and The University of Texas MD Anderson Cancer Center, today announced a strategic alliance focusing on building the next generation of precision medicine software for radiation oncology.

• share
• favorite_border

Dana-Farber Cancer Institute scientists report a number of patients in a small study with RAS-driven lung, ovarian, and thyroid cancers got long-term clinical benefit from a combination of two drugs that targeted molecular pathways controlled by the RAS gene.

• share
• favorite_border

New Dana-Farber study shows patients with platinum resistant ovarian cancer who wouldn’t be expected to respond to a PARP inhibitor had partial shrinkage of their tumor with the addition of a kinase inhibitor.

• share
• favorite_border

Dr. Marie Bleakley, a pediatric oncology physician-scientist at Fred Hutchinson Cancer Research Center, has received a 2017 Innovative Research Grant in immuno-oncology from Stand Up To Cancer.

• share
• favorite_border

New research suggests that some patients with head and neck cancers can benefit by continuing treatment with an immunotherapy drug after their tumors show signs of enlargement according to investigators at Dana-Farber Cancer Institute and other organizations.

• share
• favorite_border

What if your body’s ancient defenses against invading bacteria could be hijacked to help kill cancer? In a small sarcoma trial, Fred Hutch scientists led by Dr. Seth Pollack see signs of immune attack after injections of a bacteria-inspired drug.

• share
• favorite_border

An Innovative Research Grant from Stand Up to Cancer will help a University of Texas MD Anderson Cancer Center physician scientist and her team understand how the bacteria in the digestive tracts of melanoma patients affects their response to a common immunotherapy drug.

• share
• favorite_border

NCCN Imaging AUC™ provide a single access point for all oncology imaging recommendations within the NCCN Guidelines®; currently, NCCN Imaging AUC™ are available for 48 NCCN Guidelines.

• share
• favorite_border

Research has shown that by themselves, the diabetes drug metformin and cholesterol-lowering drugs known as statins are associated with reduced cancer mortality, but little is known about the effect on pancreatic cancer mortality when these drugs are taken together. Investigators at Rutgers Cancer Institute of New Jersey examined SEER Medicare data to further explore this approach and found that exposure to statins for these patients was significantly associated with reduced overall mortality.

• share
• favorite_border

Research findings from Memorial Sloan Kettering Cancer Center (MSK) will be featured in this year’s American Association for Cancer Research (AACR) Annual Meeting press program. The AACR is the oldest and largest professional organization dedicated to advancing cancer research, and the press program highlights cancer research that a panel of AACR experts considers the most significant of the year and deserving of media attention.

• share
• favorite_border

Dr. Amanda Paulovich, whose lab has a leading role in the Beau Biden Cancer Moonshot, will speak April 5 at the AACR annual meeting about her lab’s pioneering methods to measure proteins that serve as tumor markers.

• share
• favorite_border

A Yale Cancer Center team analyzed HNSCC data from The Cancer Genome Atlas to identify molecular characteristics of HPV+ HNSCC and correlated them with patient outcomes.

• share
• favorite_border

Workers exposed to chemicals like deodorizers, sanitizers, disinfectants and sterilizers on the job may be more likely than other people to develop thyroid cancer, a recent study suggests.

• share
• favorite_border

A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen deprivation therapy (ADT) – a testosterone-lowering therapy and a common treatment for the disease – and dementia, according to researchers from the Perelman School of Medicine at the University of Pennsylvania.

• share
• favorite_border

The Kevin Rudi Foundation will host its third annual Superhero 5K Fun Run to raise money for sarcoma research at The University of New Mexico Comprehensive Cancer Center.

• share
• favorite_border

Ludwig Cancer Research released today the full scope of advances to be presented by Ludwig researchers at this year’s American Association for Cancer Research (AACR) Annual Meeting in Washington D.C., April 1-5, 2017.

• share
• favorite_border

Scientists from the Fred Hutchinson Cancer Research Center in Seattle are scheduled to present and discuss the latest developments in immunotherapy and proteomics at the American Association for Cancer Research Annual Meeting, Research Propelling Cancer Prevention and Cures, on April 1-5. What follows is a selection of the more than 30 Hutch presentations at the AACR gathering

• share
• favorite_border

More than 1,600 oncology professionals attended the NCCN 22nd Annual Conference in Orlando, Florida

• share
• favorite_border

Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

In the first time addressing a public forum together, Kalanithi’s widow, Lucy Kalanithi, MD, Clinical Assistant Professor of Medicine at Stanford School of Medicine; and Paul’s treating oncologist, Heather Wakelee, MD, Associate Professor of Medicine at Stanford Cancer Institute, spoke about their experiences on March 24, 2017 during the National Comprehensive Cancer Network® (NCCN®) 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™.

• share
• favorite_border

David M. Livingston, MD, of Dana-Farber Cancer Institute, has won a major award for discoveries in cancer research from the American Association for Cancer Research (AACR).

• share
• favorite_border

Judy E. Garber, MD, MPH, director of the Center for Cancer Genetics and Prevention at Dana-Farber Cancer Institute, has been honored by the American Association for Cancer Research (AACR) for outstanding achievement in clinical cancer research.

• share
• favorite_border

NCCN Conference Roundtable Addresses Health Disparities

• share
• favorite_border

NCCN Foundation Young Investigator Awards provide grants of $150,000 over a two-year period for research initiatives focused on assessing and improving outcomes in cancer care.

• share
• favorite_border

While an HPV vaccine became available over 10 years ago, a study led by the Yale School of Public Health finds that there is “substantial” room for improvement in the way it is recommended and discussed.

• share
• favorite_border

A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, and one of the most deadliest with a less than 10 percent, five-year survival rate. PRMT1 is involved in a number of genetic processes including gene transcription, DNA repair and signaling.

• share
• favorite_border

Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways to chill an immune attack after one immunotherapy drug fires up the immune system, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine.

• share
• favorite_border

The U.S. Food and Drug Administration yesterday granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma. Dr. Paul Nghiem, a senior investigator on the clinical trial that led to yesterday’s fast-track FDA approval and an expert on MCC is available for interviews, as is a patient who participated in the clinical trial.

• share
• favorite_border

A $9.5 million, five-year grant from the National Cancer Institute (NCI) will fund an intensive multidisciplinary research effort that seeks to better understand how cancer cells reach an aggressive state and begin to damage surrounding tissue.

• share
• favorite_border

Gena Cook, Co-Founder and Chief Executive Officer, Navigating Cancer, and Heather Kopecky, PhD, MBA, Senior Client Partner, Korn Ferry, have been named Chair and Vice-Chair, respectively, of the NCCN Foundation Board of Directors.

• share
• favorite_border

In a new study published today in JCI Insight, UC Davis researchers have shown that combining high-intensity focused ultrasound with two immunotherapies (a PD-1 checkpoint inhibitor and TLR9 agonist) can produce excellent response rates in mouse models of epithelial cancer. They also found that, for the combination to be effective, immunotherapies must come first.

• share
• favorite_border

Researchers from Memorial Sloan Kettering Cancer Center (MSK) have identified, for the first time, an epigenetic mechanism promoting breast cancer. The team found that inhibition of the PI3K pathway leads to activation of ER-dependent transcription through the epigenetic regulator KMT2D. These findings provide a rationale for epigenetic therapy in patients with PIK3CA-mutant, ER-positive breast cancer. While epigenetic factors have been known to play an important role in various cancers such as leukemia and lymphoma, this is the first evidence found in breast cancer.

• share
• favorite_border

Launched during the NCCN 22nd Annual Conference, the new NCCN Radiation Therapy Compendium™ provides a single access point for radiation therapy recommendations within the NCCN Guidelines®.

• share
• favorite_border

A ‘first in human’ clinical trial examining the small molecule drug ONC201 in cancer patients with advanced solid tumors shows that this investigational drug is well tolerated at the recommended phase II dose. That’s according to Rutgers Cancer Institute of New Jersey investigators whose research also showed early signs of clinical benefit in patients with advanced prostate and endometrial cancers.

• share
• favorite_border

Dana-Farber Cancer Institute and Lifespan leadership are creating a strategic alliance to advance cancer treatment and research.

• share
• favorite_border